Galderma's CEO Flemming Ørnskov revealed that the rising use of GLP-1 weight-loss medications like Ozempic and Wegovy is driving strong growth in the company's aesthetics portfolio, including fillers and anti-wrinkle treatments. About 10% of U.S. adults now use these drugs, creating demand for products that address facial sagging linked to significant weight loss, a condition sometimes called "Ozempic face." Galderma reported nearly 25% sales growth year-on-year at constant currencies, with U.S. sales growing 32%, outpacing other regions. This trend presents a significant but early-stage opportunity for the company in the aesthetics market.
Data from Santiment shows 85 new XRP Ledger addresses holding at least 1 million XRP emerged just two days before XRP's price surged 67% between August 17 and 21. This increase in large wallets preceded the rally, suggesting whale activity might have...
SwissBorg has integrated direct USDC deposits on the Arc Network, allowing users to transfer stablecoins without using third-party bridges that charge high fees, sometimes up to 25%. This integration makes SwissBorg a direct on-ramp to Arc, a stablec...
H100 CEO Eirik Grøttum purchased 407,163 shares of H100 through his associated company Kode Oslo for SEK 621,887, increasing insider holdings to over 5.3 million shares. This equity purchase is separate from H100's Bitcoin treasury, which remains at ...
XRP Ledger activity has surged, causing the XRP burn rate from transaction fees to rise above its recent average, with about 337 XRP burned recently compared to the 30-day average of 319 XRP. This increase reflects higher network usage, as transactio...
Broadcom, JPMorgan Chase, and Coca-Cola have each delivered substantial long-term returns through durable earnings and dividends. Broadcom benefits from booming AI semiconductor demand, projecting $230 billion revenue in fiscal 2028. JPMorgan Chase c...
